Who
Alan Ezekowitz
Director
Company insider
Files Form 4 as: Director, Fulcrum Therapeutics; Director, Septerna; Director, Organon & Co.
In numbers
- Trades disclosed
- 27
- Buys
- 4
- Sells
- 1
- Bought
- $608K
- Sold
- $131K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 18 Jul 2019
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K18,000 at $3.65 | filing |
| 26 Jun 2026filed 30 Jun 2026 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K18,000 at $3.65 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $240K17,857.143 at $13.44 | filing |
| 12 Jun 2026filed 15 Jun 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $240K17,857.14 at $13.44 | filing |
| 26 Jun 2025filed 30 Jun 2025 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,623 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $240K23,904.38 at $10.04 | filing |
| 7 Mar 2025filed 10 Mar 2025 | SEPN SepternaBiotechnology | SEC FORM 4 Bought | $92K13,319 at $6.93 | filing |
| 6 Mar 2025filed 6 Mar 2025 | SEPN SepternaBiotechnology | SEC FORM 4 Bought | $248K41,355 at $6.00 | filing |
| 5 Mar 2025filed 6 Mar 2025 | SEPN SepternaBiotechnology | SEC FORM 4 Bought | $220K37,835 at $5.82 | filing |
| 4 Mar 2025filed 6 Mar 2025 | SEPN SepternaBiotechnology | SEC FORM 4 Bought | $48K7,491 at $6.35 | filing |
| 17 Jun 2024filed 18 Jun 2024 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 7 Jun 2024filed 11 Jun 2024 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $200K9,638.55 at $20.75 | filing |
| 27 Jun 2023filed 29 Jun 2023 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2023filed 13 Jun 2023 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $200K10,086 at $19.83 | filing |
| 28 Jun 2022filed 29 Jun 2022 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.